secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001104659-24-028724
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q4 revenue up 43% to $311M; net loss narrows; guides 2024 rev $1.32-1.35B
--------------------------------------------------------------------------------

- Q4 revenue $311.1M (+43.2% YoY); product revenue up 44.3% to $307.3M.
- Net loss per share Q4 ($0.65) vs ($1.37) prior year; full year loss ($3.78) vs ($5.57).
- Gross margin Q4 51.4% vs 41.4% YoY; full year 45.5% vs 44.4%.
- Oncology tests Q4 up 52.3% to 97,500; FY up 73.5% to 340,700.
- FY2024 guidance: revenue $1.32-1.35B; gross margin 50-53%; net cash consumption $50-75M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465924028724/0001104659-24-028724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465924028724/tm247042d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-028724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer